conv.

← The whole story
Health
FDA panel votes on Grail's Galleri multi-cancer blood test

Medicare coverage floated as approval's likely payoff

4 Today 8:39 AM · 14h ago · 1 article · 1 source · development 4 of 6

Coverage notes that FDA approval could pave the way for Medicare reimbursement, even though a major study of the test failed to prove it could detect later-stage cancers.

Medicare coverage floated as approval's likely payoff
STAT News

Grail Inc. Maker of the Galleri multi-cancer blood testFDA Molecular and Clinical Genetics Panel Independent advisory panelVinay Prasad Former FDA biologics chiefWSJ Editorial Board Opinion commentator

The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump

Peak 6 pieces in one hour at Today, 9 AM; 27 pieces over 3 days (18 articles · 9 posts) Sep 20, 4 PM — 1 piece · 1 article — Newswires 1Sep 20, 5 PM — quietSep 20, 6 PM — quietSep 20, 7 PM — quietSep 20, 8 PM — quietSep 20, 9 PM — quietSep 20, 10 PM — quietSep 20, 11 PM — quietSep 21, 12 AM — quietSep 21, 1 AM — quietSep 21, 2 AM — quietSep 21, 3 AM — quietSep 21, 4 AM — 1 piece · 1 article — Newswires 1Sep 21, 5 AM — quietSep 21, 6 AM — quietSep 21, 7 AM — quietSep 21, 8 AM — quietSep 21, 9 AM — quietSep 21, 10 AM — quietSep 21, 11 AM — quietSep 21, 12 PM — quietSep 21, 1 PM — 1 piece · 1 article — Newswires 1Sep 21, 2 PM — quietSep 21, 3 PM — 3 pieces · 3 articles — Google News 3Sep 21, 4 PM — quietSep 21, 5 PM — quietSep 21, 6 PM — quietSep 21, 7 PM — quietSep 21, 8 PM — quietSep 21, 9 PM — quietSep 21, 10 PM — quietSep 21, 11 PM — quietYesterday, 12 AM — quietYesterday, 1 AM — quietYesterday, 2 AM — quietYesterday, 3 AM — quietYesterday, 4 AM — quietYesterday, 5 AM — quietYesterday, 6 AM — quietYesterday, 7 AM — quietYesterday, 8 AM — quietYesterday, 9 AM — quietYesterday, 10 AM — quietYesterday, 11 AM — quietYesterday, 12 PM — quietYesterday, 1 PM — quietYesterday, 2 PM — quietYesterday, 3 PM — quietYesterday, 4 PM — quietYesterday, 5 PM — quietYesterday, 6 PM — quietYesterday, 7 PM — quietYesterday, 8 PM — quietYesterday, 9 PM — quietYesterday, 10 PM — quietYesterday, 11 PM — quietToday, 12 AM — quietToday, 1 AM — quietToday, 2 AM — quietToday, 3 AM — quietToday, 4 AM — quietToday, 5 AM — 5 pieces · 2 articles · 3 posts — Mastodon 3, Newswires 2Today, 6 AM — 1 piece · 1 post — Mastodon 1Today, 7 AM — quietToday, 8 AM — 2 pieces · 2 articles — Newswires 2Today, 9 AM — 6 pieces · 4 articles · 2 posts — Newswires 4, Mastodon 2Today, 10 AM — quietToday, 11 AM — quietToday, 12 PM — quietToday, 1 PM — quietToday, 2 PM — quietToday, 3 PM — quietToday, 4 PM — 2 pieces · 1 article · 1 post — Mastodon 1, Newswires 1Today, 5 PM — 1 piece · 1 article — Newswires 1Today, 6 PM — 4 pieces · 2 articles · 2 posts — Google News 2, Mastodon 2Today, 7 PM — quietToday, 8 PM — quietToday, 9 PM — quietToday, 10 PM — quiet 1234–6
1WSJ editorial board urges FDA to clear…2Grail shares surge 33% on FDA meeting…3FDA's outside expert panel meets to vote…4–6Medicare coverage floated as approval's…
Sep 21yesterdaytodaynow · 11:23 PM ET

What was reported 1 claim about this development

  1. 1 outlet FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

    first by MarketWatch, 14h ago

All 6 developments of FDA panel votes on Grail's Galleri multi-cancer blood test →

NewswiresGoogle NewsMastodon